Printed From BioPortfolio.com
Barriers to access to biosimilars
04:34 EDT 13 Oct 2017 | Generics and Biosimilars Initiative
Barriers to the use of biosimilars include healthcare professional and patient opinions. But national and local guidelines, levels of funding and differing approaches to healthcare management can also influence access to biosimilars in different Member States of the European Union (EU), according to authors from the National Advisory Unit on Rehabilitation in Rheumatology and the Rheumatology Department of Diakonhjemmet Hospital, Oslo, Norway [1].
Original Article: Barriers to access to biosimilars
